Mashup Score: 2
American Society of HematologyTO THE EDITOR:
See more from Akiva Diamond
in a retrospective review of 133 patients treated with polaBR for relapsed / refractory DLBCL showed a 57% ORR and a 31% CR rate, median PFS was 4.8 months and median OS was 8.2 months.